FDA approves Dupixent for COPD with eosinophilic phenotype
300% citation coverage2 regulatory sources
The FDA has approved Dupixent as an add-on maintenance treatment for adults with inadequately controlled COPD and an eosinophilic phenotype. The decision gives Regeneron and Sanofi a new regulatory catalyst to track for commercial and investor implications.
Intelligence Snapshot
Executive Summary
The FDA has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with inadequately controlled COPD and an eosinophilic phenotype, marking the drug's first COPD indication.
Key Insights
-
Dupixent is an interleukin-4 receptor alpha antagonist now indicated for atopic…
Dupixent is an interleukin-4 receptor alpha antagonist now indicated for atopic dermatitis, asthma, and COPD with eosinophilic phenotype.
-
Ongoing phase 3 and phase 4 dupilumab trials in chronic spontaneous urticaria and atopic…
Ongoing phase 3 and phase 4 dupilumab trials in chronic spontaneous urticaria and atopic dermatitis continue to recruit.
Market Impact
| Regulatory | high |
|---|---|
| Commercial | high |
| Competitive | medium |
| Investment | high |
Loading intelligence…
Loading intelligence…
Loading intelligence…
Loading intelligence…
Loading intelligence…
Quick Answer
The FDA has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with inadequately controlled COPD and an eosinophilic phenotype, marking the drug's first COPD indication.
Key Questions
- What changed with the Dupixent approval?
- Who makes Dupixent and what pharmaceutical company commercializes it?
- What should BD and investor teams watch next?
- What is dupilumab's mechanism of action?
- Are there limitations on how Dupixent can be used in respiratory disease?
Executive Scorecard
Heuristic scores · directional, not investment adviceRegulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for Dupixent.
Unlock full calendar →Regeneron pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Investor brief
Download a one-page summary of regulatory impact and competitive context.
Explore drug hub →Contents14 sections
FDA Approves Dupixent for COPD with Eosinophilic Phenotype
The FDA has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with inadequately controlled COPD and an eosinophilic phenotype. Regeneron Pharmaceuticals and Sanofi jointly announced the dupilumab COPD approval, marking the first time the blockbuster immunology drug has been cleared for the respiratory indication.
IntelligenceRegulatory Impact
FDA decisions frame this story. Regulatory relevance is high for chronic obstructive pulmonary disease, with Dupixent and dupilumab most exposed. Track designations, submission types, and label or guidance shifts that could move timelines.
When was Dupixent approved for COPD?
Regeneron Pharmaceuticals and Sanofi announced that the FDA has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. The approval expands the drug's labeled respiratory indications beyond asthma and atopic dermatitis.
IntelligenceCompetitive Intelligence
Regeneron, Regeneron Pharmaceuticals Inc, and Sanofi are directly implicated. Competitive pressure reads medium — compare pipeline positioning and partnership scouting against signals in this story.
What is Dupixent's mechanism and current labeled uses?
Dupixent is an interleukin-4 receptor alpha antagonist. Prior to this approval, Dupixent was indicated for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis, and as an add-on maintenance treatment for adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma. Importantly, Dupixent is not indicated for the relief of acute bronchospasm or status asthmaticus, a limitation that applies across all respiratory indications.
IntelligenceMarket Signals
Commercial pull is high and investment relevance high for chronic obstructive pulmonary disease. Expect implications for pricing, access, and launch sequencing.
What pharmaceutical company makes Dupixent?
The FDA label lists dupilumab as manufactured by Sanofi-Aventis U.S. LLC, with the brand name Dupixent. Regeneron Pharmaceuticals and Sanofi jointly announced the approval.
IntelligenceStrategic Takeaways
The FDA has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with inadequately controlled COPD and an eosinophilic phenotype, marking the drug's first COPD indication. Dupixent is an interleukin-4 receptor alpha antagonist now indicated for atopic dermatitis, asthma, and COPD with eosinophilic phenotype. Ongoing phase 3 and phase 4 dupilumab trials in chronic spontaneous urticaria and atopi
Pipeline Monitoring Stays Important for Dupilumab
Beyond the COPD approval, dupilumab development continues in other indications tracked on ClinicalTrials.gov. A phase 3 trial (NCT06868212) is currently recruiting to evaluate dupilumab compared to remibrutinib in adults with chronic spontaneous urticaria inadequately controlled by second-generation antihistamines, sponsored by Novartis.
A phase 4 trial (NCT05858619) is recruiting to study molecular signatures of cutaneous dupilumab response in atopic dermatitis, sponsored by the University of California, San Francisco.
IntelligenceEvidence Quality
Grounded in 2 regulatory sources.
Key Takeaways
- The FDA has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with inadequately controlled COPD and an eosinophilic phenotype, marking the drug's first COPD indication.
- Dupixent is an interleukin-4 receptor alpha antagonist now indicated for atopic dermatitis, asthma, and COPD with eosinophilic phenotype.
- Ongoing phase 3 and phase 4 dupilumab trials in chronic spontaneous urticaria and atopic dermatitis continue to recruit.
Drug Snapshot
| Drug | dupilumab |
|---|---|
| Generic name | DUPILUMAB |
| Drug class | Interleukin-4 Receptor alpha Antagonist [EPC] |
| Manufacturer | Sanofi-Aventis U.S. LLC |
| Route | SUBCUTANEOUS |
| Indication | 1 INDICATIONS AND USAGE DUPIXENT is an interleukin-4 receptor alpha antagonist indicated: Atopic Dermatitis for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids. ( 1.1 ) Asthma as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid |
Regulatory Summary
- Approved indication: 1 INDICATIONS AND USAGE DUPIXENT is an interleukin-4 receptor alpha antagonist indicated: Atopic Dermatitis for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids. ( 1.1 ) Asthma as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid
- dupilumab is_class Interleukin-4 Receptor alpha Antagonist [EPC]
- Sanofi-Aventis U.S. LLC develops dupilumab
Trial Snapshot
| Trial | Title | Status | Phase | Sponsor |
|---|---|---|---|---|
| NCT06868212 | A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines | RECRUITING | PHASE3 | Novartis Pharmaceuticals |
| NCT05070663 | A Study in Male and Female Adolescent Participants With Severe Uncontrolled Asthma Starting Treatment With Dupilumab Injection (Dupixent®) | COMPLETED | — | Sanofi |
| NCT05436535 | Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis | COMPLETED | PHASE4 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT06881251 | A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD) | TERMINATED | PHASE2 | Janssen Research & Development, LLC |
| NCT05858619 | Molecular Signatures of Cutaneous Dupilumab Response | RECRUITING | PHASE4 | University of California, San Francisco |
Competitor Matrix
| Company / Program | Indication | Active trials |
|---|---|---|
| National Cancer Institute (NCI) | chronic obstructive pulmonary disease | 2 |
| VA Office of Research and Development | chronic obstructive pulmonary disease | 1 |
| Tel-Aviv Sourasky Medical Center | chronic obstructive pulmonary disease | 1 |
| University of Alcala | chronic obstructive pulmonary disease | 1 |
| Reistone Biopharma Company Limited | chronic obstructive pulmonary disease | 1 |
| Janssen Research & Development, LLC | chronic obstructive pulmonary disease | 1 |
Timeline
- Recruiting trial NCT06868212 (PHASE3)
- Recruiting trial NCT05858619 (PHASE4)
- Recruiting trial NCT06868212 (PHASE3)
- Recruiting trial NCT05858619 (PHASE4)
Frequently Asked Questions
What changed with the Dupixent approval?
The FDA approved Dupixent for adults with inadequately controlled COPD and an eosinophilic phenotype as an add-on maintenance treatment. This is a new indication; prior labels covered atopic dermatitis and asthma, but not COPD.
Who makes Dupixent and what pharmaceutical company commercializes it?
Dupixent is manufactured by Sanofi-Aventis U.S. LLC. Regeneron Pharmaceuticals and Sanofi jointly announced the COPD approval.
What should BD and investor teams watch next?
Track readouts from the phase 3 chronic spontaneous urticaria trial (NCT06868212) and the phase 4 atopic dermatitis biomarker study (NCT05858619), both currently recruiting.
What is dupilumab's mechanism of action?
Dupixent is an interleukin-4 receptor alpha antagonist.
Are there limitations on how Dupixent can be used in respiratory disease?
Yes. Dupixent is not indicated for the relief of acute bronchospasm or status asthmaticus. It is approved only as an add-on maintenance treatment, not for acute exacerbations or emergency respiratory crises.
Related profiles
Related coverage
Continue Exploring
Jump into the entities behind this story.
Ask AI About chronic obstructive pulmonary disease
Grounded in NovaPharmaNews intelligence. Pick a prompt to start.
Follow Dupixent developments
FDA chronic obstructive pulmonary disease alerts and Dupixent pipeline updates, every Monday.
- Sources analyzed
- 2
- Evidence strength
- 100/100
- Last verified
- Jun 7, 2026
- AI-assisted review
- Yes
- Editorial review
- Dr. Sarah Chen
Critical source quality · grounded in cited primary and secondary sources.
This article follows our editorial standards. Report a correction via editorial contact.
